Discovery of 2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-one derivatives as possible antileishmanial agents
This journal is © The Royal Society of Chemistry..
A series of uniquely functionalized 2,3,-dihydro-1H-pyyrolo[3,4-b]quinolin-1-one derivatives were synthesized in one to two steps by utilizing a post-Ugi modification strategy and were evaluated for antileishmanial efficacy against visceral leishmaniasis (VL). Among the library compounds, compound 5m exhibited potential in vitro antileishmanial activity (CC50 = 65.11 μM, SI = 7.79, anti-amastigote IC50 = 8.36 μM). In vivo antileishmanial evaluation of 5m demonstrated 56.2% inhibition in liver and 61.1% inhibition in spleen parasite burden in infected Balb/c mice (12.5 mg kg-1, i.p.). In vitro pharmacokinetic study ascertained the stability of 5m in both simulated gastric fluid and simulated intestinal fluid. All the active compounds passed the PAINS filter and showed no toxicity in in silico predictions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
RSC medicinal chemistry - 13(2022), 6 vom: 22. Juni, Seite 746-760 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seth, Anuradha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 13.05.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1039/d2md00078d |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343354101 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343354101 | ||
| 003 | DE-627 | ||
| 005 | 20231226020243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1039/d2md00078d |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343354101 | ||
| 035 | |a (NLM)35814931 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seth, Anuradha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discovery of 2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-one derivatives as possible antileishmanial agents |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.05.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a This journal is © The Royal Society of Chemistry. | ||
| 520 | |a A series of uniquely functionalized 2,3,-dihydro-1H-pyyrolo[3,4-b]quinolin-1-one derivatives were synthesized in one to two steps by utilizing a post-Ugi modification strategy and were evaluated for antileishmanial efficacy against visceral leishmaniasis (VL). Among the library compounds, compound 5m exhibited potential in vitro antileishmanial activity (CC50 = 65.11 μM, SI = 7.79, anti-amastigote IC50 = 8.36 μM). In vivo antileishmanial evaluation of 5m demonstrated 56.2% inhibition in liver and 61.1% inhibition in spleen parasite burden in infected Balb/c mice (12.5 mg kg-1, i.p.). In vitro pharmacokinetic study ascertained the stability of 5m in both simulated gastric fluid and simulated intestinal fluid. All the active compounds passed the PAINS filter and showed no toxicity in in silico predictions | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Ghoshal, Anirban |e verfasserin |4 aut | |
| 700 | 1 | |a Dewaker, Varun |e verfasserin |4 aut | |
| 700 | 1 | |a Rani, Ankita |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sangh Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Dutta, Mukul |e verfasserin |4 aut | |
| 700 | 1 | |a Katiyar, Shivani |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sandeep Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Rashid, Mamunur |e verfasserin |4 aut | |
| 700 | 1 | |a Wahajuddin, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Kar, Susanta |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Ajay Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t RSC medicinal chemistry |d 2020 |g 13(2022), 6 vom: 22. Juni, Seite 746-760 |w (DE-627)NLM320418669 |x 2632-8682 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:6 |g day:22 |g month:06 |g pages:746-760 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1039/d2md00078d |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 6 |b 22 |c 06 |h 746-760 | ||